Graham Rena

List of Publications by Year
in descending order

38 papers	5,610 citations	304602 22 h-index	302012 39 g-index
39 all docs	39 docs citations	39 times ranked	8297 citing authors

#	Article	IF	Citations
1	Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention. Frontiers in Cardiovascular Medicine, 2021, 8, 746382.	1.1	23
2	Metformin: still the sweet spot for CV protection in diabetes?. Current Opinion in Pharmacology, 2020, 54, 202-208.	1.7	11
3	In a cohort of individuals with type 2 diabetes using the drug sulfasalazine, HbA 1c lowering is associated with haematological changes. Diabetic Medicine, 2020, 38, e14463.	1.2	1
4	Editorial: Metformin: Beyond Diabetes. Frontiers in Endocrinology, 2019, 10, 851.	1.5	12
5	Repurposing Metformin for Cardiovascular Disease. Circulation, 2018, 137, 422-424.	1.6	100
6	Metformin selectively targets redox control of complex I energy transduction. Redox Biology, 2018, 14, 187-197.	3.9	115
7	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Associationâ€"European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	1.0	171
8	Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1). Diabetes, Obesity and Metabolism, 2018, 20, 2748-2758.	2.2	10
9	The mechanisms of action of metformin. Diabetologia, 2017, 60, 1577-1585.	2.9	1,421
10	New Evidence for the Mechanism of Action of a Type-2 Diabetes Drug Using a Magnetic Bead-Based Automated Biosensing Platform. ACS Sensors, 2017, 2, 1329-1336.	4.0	7
11	Investigation of salicylate hepatic responses in comparison with chemical analogues of the drug. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1412-1422.	1.8	8
12	Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circulation Research, 2016, 119, 652-665.	2.0	498
13	The copper binding properties of metformin â€" QCM-D, XPS and nanobead agglomeration. Chemical Communications, 2015, 51, 17313-17316.	2.2	20
14	Biomolecular Mode of Action of Metformin in Relation to Its Copper Binding Properties. Biochemistry, 2014, 53, 787-795.	1.2	46
15	Salicylic acid: old and new implications for the treatment of type 2 diabetes?. Diabetology International, 2014, 5, 212-218.	0.7	16
16	Molecular mechanism of action of metformin: old or new insights?. Diabetologia, 2013, 56, 1898-1906.	2.9	376
17	The anti-neurodegenerative agent clioquinol regulates the transcription factor FOXO1a. Biochemical Journal, 2012, 443, 57-64.	1.7	9
18	Cellular Responses to the Metal-Binding Properties of Metformin. Diabetes, 2012, 61, 1423-1433.	0.3	85

#	Article	IF	Citations
19	Molecular action and pharmacogenetics of metformin: current understanding of an old drug. Diabetes Management, 2012, 2, 439-452.	0.5	15
20	Zinc-dependent effects of small molecules on the insulin-sensitive transcription factor FOXO1a and gluconeogenic genes. Metallomics, 2010, 2, 195-203.	1.0	21
21	Black tea polyphenols mimic insulin/insulinâ€like growth factorâ€1 signalling to the longevity factor FOXO1a. Aging Cell, 2008, 7, 69-77.	3.0	50
22	Epigallocatechin gallate (EGCG) mimics insulin action on the transcription factor FOXO1a and elicits cellular responses in the presence and absence of insulin. Cellular Signalling, 2007, 19, 378-383.	1.7	63
23	D4476, a cellâ€permeant inhibitor of CK1, suppresses the siteâ€specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Reports, 2004, 5, 60-65.	2.0	232
24	Insulin Regulation of Insulin-like Growth Factor-binding Protein-1 Gene Expression Is Dependent on the Mammalian Target of Rapamycin, but Independent of Ribosomal S6 Kinase Activity. Journal of Biological Chemistry, 2002, 277, 9889-9895.	1.6	40
25	Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. EMBO Journal, 2002, 21, 2263-2271.	3.5	205
26	Molecular Cloning, Genomic Positioning, Promoter Identification, and Characterization of the Novel Cyclic AMP-Specific Phosphodiesterase PDE4A10. Molecular Pharmacology, 2001, 59, 996-1011.	1.0	70
27	Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting. Biochemical Journal, 2001, 354, 605.	1.7	152
28	Antagonistic effects of phorbol esters on insulin regulation of insulin-like growth factor-binding protein-1 (IGFBP-1) but not glucose-6-phosphatase gene expression. Biochemical Journal, 2001, 359, 611.	1.7	10
29	Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting. Biochemical Journal, 2001, 354, 605-612.	1.7	227
30	The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. Biochemical Journal, 2001, 355, 597-607.	1.7	247
31	Antagonistic effects of phorbol esters on insulin regulation of insulin-like growth factor-binding protein-1 (IGFBP-1) but not glucose-6-phosphatase gene expression. Biochemical Journal, 2001, 359, 611-619.	1.7	15
32	Membrane Localization of Cyclic Nucleotide Phosphodiesterase 3 (PDE3). Journal of Biological Chemistry, 2000, 275, 38749-38761.	1.6	94
33	Phosphorylation of the Transcription Factor Forkhead Family Member FKHR by Protein Kinase B. Journal of Biological Chemistry, 1999, 274, 17179-17183.	1.6	639
34	Phosphorylation of Serine 256 by Protein Kinase B Disrupts Transactivation by FKHR and Mediates Effects of Insulin on Insulin-like Growth Factor-binding Protein-1 Promoter Activity through a Conserved Insulin Response Sequence. Journal of Biological Chemistry, 1999, 274, 17184-17192.	1.6	491
35	Upregulation of cAMP-specific PDE-4 activity following ligation of the TCR complex on thymocytes is blocked by selective inhibitors of protein kinase C and tyrosyl kinases. Cell Biochemistry and Biophysics, 1998, 28, 161-185.	0.9	9
36	Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2. Biochemical Journal, 1998, 333, 693-703.	1.7	45

#	Article	IF	Citations
37	Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines. Biochemical Journal, 1997, 321, 177-185.	1.7	36
38	Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase. Biochemical Journal, 1997, 321, 157-163.	1.7	19